What Is BridgeBio Oncology Therapeutics (BBOT) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, BridgeBio Oncology Therapeutics's intrinsic value is estimated at $3.59, suggesting the stock is overvalued at its current price of $8.41. With 7 out of 9 models flagging downside (-57.4% average return), the market may be pricing in unsustainable growth. Notably, FTNN sees the most upside at +13.6% (fair value: $9.55), while ML-RIV is the most conservative at -97.1% ($0.25). The spread between these extremes — +110.6% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About BBOT?
9 of 13 models are currently active for BBOT. Of these, 2 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates BBOT's intrinsic value at $4.33, implying -48.6% downside from the current price. See which stocks rank higher →
How Does BBOT Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, BBOT ranks #147 by Quality of Company score. CirclFi's QOC score of 5.7/10 evaluates 32 fundamental signals. A score of 5.7 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, BridgeBio Oncology Therapeutics competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is BBOT a Value Trap?
The Value Trap algorithm is not active for BBOT. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for BridgeBio Oncology Therapeutics. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, BridgeBio Oncology Therapeutics is rated at 5.7/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +110.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every BBOT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across BBOT's 9 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad